Marion Flipo is an Associate Professor of Organic and Medicinal Chemistry at the School of Pharmacy, University of Lille, France. Her research focuses on developing new strategies to combat antimicrobial resistance in Mycobacterium tuberculosis and Gram-negative bacterial infections. She has extensively worked on optimising boosters of the anti-tuberculosis drug ethionamide, resulting in the successful development of Alpibectir, a clinical candidate currently in phase 2 trials.
Currently, Marion leads a medicinal chemistry programme dedicated to optimising efflux pump inhibitors to tackle Gram-negative infections. She earned her PhD in Medicinal Chemistry from the University of Lille. After completing a postdoctoral fellowship at the Ferring Research Institute in San Diego, CA, she joined the University of Lille in 2008 as an Assistant Professor.